Merck
Merck signs Theravance cardio deal
October 19, 2012Sales and Marketing Merck, Theravance, cardiovascular
Merck has signed a deal with US biopharma firm Theravance to discover and develop novel small molecules to treat cardiovascular …
Merck enters €110m virus alliance
October 16, 2012Research and Development, Sales and Marketing AiCuris, Gilead, HCMV, Merck
Merck has gained access to AiCuris’ portfolio of investigational medicines targeting human cytomegalovirus (HCMV) via a global licensing agreement. It …
Merck gives back vernakalant rights
September 28, 2012Sales and Marketing AF, Cardiome, Merck, vernakalant
Merck has dealt a further blow to Cardiome Pharma Corp by handing back all marketing and development rights for the …
Merck releases new Phase III insomnia data
September 11, 2012Research and Development, Sales and Marketing Merck, insomnia, suvorexant
Merck says it is on course to file its investigational insomnia drug suvorexant in the US by the end of …
Pfizer meets targets on greenhouse gases
August 16, 2012Manufacturing and Production GHGs, Merck, Pfizer
Pfizer says it has fulfilled its goal of cutting environmentally-harmful emissions from its facilities by 20%, a year ahead of …
Merck’s Singulair faces generic rivals
August 7, 2012Sales and Marketing Merck, Singulair, generic erosion, patent
Merck has lost patent protection on its biggest selling drug Singulair, opening the floodgates for generic rivals. Merck’s drug brought …
Merck sees growth in second quarter
July 30, 2012Sales and Marketing Cozaar, Merck, Q2, Singulair
Merck has posted a healthy sales increase for the second quarter, as its established drugs grew strongly. Sales increased 1% …
Merck closes Cherokee Pharma plant
July 3, 2012Manufacturing and Production API, Cherokee Pharmaceuticals, Merck, manufacturing
Merck & Co has decided to close down part of a US plant operated by subsidiary Cherokee Pharmaceuticals after failing …
Merck’s sleep aid drug meets goals
June 15, 2012Research and Development, Sales and Marketing FDA, Merck, insomnia, sleep disorder, suvorexant
Merck’s novel insomnia drug suvorexant has improved patients’ ability to fall asleep, according to new data from two Phase III …
Merck extends biocatalysis collaboration with Codexis
May 29, 2012Manufacturing and Production Codexis, Merck, Phil Taylor, Victrelis, manufacturing
Biocatalyst specialist Codexis has signed a three-year extension of its catalyst and process development collaboration with Merck to develop enzymes …
FDA approves greener process for Januvia production
May 1, 2012Manufacturing and Production Codexis, FDA, Januvia, Merck, manufacturing
The US Food and Drug Administration (FDA) has approved a new, more environmentally-friendly manufacturing process for Merck & Co’s diabetes …
AstraZeneca diabetes drug recommended in Europe
April 23, 2012Sales and Marketing AstraZeneca, CHMP, FDA, Merck, WHO, diabetes
AstraZeneca and Bristol-Myers Squibb’s new type II diabetes treatment Forxiga has received a positive opinion by European regulators. The European …
Merck does cancer drug deal with Endocyte
April 17, 2012Research and Development, Sales and Marketing Cancer, Endocyte, Merck, NSCLC, vintafolide
Merck is to pay $120 million to US biopharma company Endocyte as part of a deal to develop and commercialise …
Merck signs deal with venture capitalists
April 16, 2012Research and Development, Sales and Marketing Flagship Ventures, Merck
Merck has entered a deal with a US venture capital firm specialising in life sciences to help build the manufacturer’s …
Januvia gains renal impairment licence in UK
April 13, 2012Sales and Marketing Januvia, MSD, Merck, diabetes, renal impairment
Merck’s Januvia has had its licence extended in the UK for patients with moderate to severe renal impairment. The drug …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
